SPI Infoamtion

1 Executive Summary
1.1 Lipitor Was the World’s Best Selling Drug In 2006
1.2 Lipitor Will Face Strong Competition After Patent Expiration In Key Markets
1.3 Lipitor Is Embroiled In Patent Challenges With Ranbaxy

2 Overview of Lipitor (Atorvastatin)
2.1 Lipitor (Atorvastatin) - The Cholesterol Reducing Drug
2.2 Obesity Is a Major Environmental Factor Associated With Dyslipidaemia
2.3 Symptoms and Signs of Dyslipidaemia
2.4 Diagnosis, Screening and Markers of Dyslipidaemia

3 Treatment of Dyslipidaemia
3.1 Lipid Regulating Drugs Are Central To Treating Dyslipidaemia
3.2 Posology And Method of Administration of Lipitor

4 Lipitor World Market Analysis
4.1 Lipid-regulating/ Anti-Atheroma Preparations Is The Largest In Cardiovascular System Market
4.2 Lipitor (Atorvastatin) Revenue Dominates all Cholesterol & Triglyceride Drugs
4.3 Lipitor’s Faces Competitions From Key Rivals In Major Markets
4.4 Pfizer’s Lipitor Challenge With Ranbaxy Will Have Significant Implications On Future Sales
4.5 US WellPoint Demonstrates Generic Statins- Lovastatin, Simvastatin And Pravastatin To Elicit Cardiovascular Benefits
4.6 Lipitor Global Sales Forecast 2008-2023
4.7 Lipitor Competes With Other Non-Statin Drugs
4.8 Pfizer Has Large Resources To Promo

5. Lipitor’s Key Patent Challenges
5.1 Patent Expiration is the Major Driver in All Generic Markets
5.2 The US Has The Largest Generics Market
5.3 The US and European Regulation of Generic Drugs
5.4 Pfizer’s Lipitor Patent Protection Sets Benchmark In Pharmaceutical Industry For Protecting Brands
5.5 Pfizer Struggles To Block Early Generic Lipitor Market Entry
5.6 The Hatch-Waxman Act, Patent Expiration and the Promotion of Generic Drugs: Title I of the Act
5.7 Ranbaxy Receives Favourable Lipitor Decisions in Key EU Markets
5.8 Lipitor Expanding Patent Contention
5.9 Ranbaxy Will Cover Cost of Legal Challenges From Sales of Atorvastatin in Key Markets

6 Lipitor- Product Life Cycle Management (PML)
6.1 Pfizer To Use Product Lifecycle Management to Drive Sales of Lipitor
6.2 Pfizer’s Prominent PLM Is Caduet- "uber-pill", a combination of Lipitor And Norvasc
6.3 Pfizer’s Torcetrapib- The Lipitor Follow-Up Drug Fails To Deliver
6.4 Pfizer Lipitor and Peripheral Vascular Diseases
6.5 Pfizer’s LEAD Trial investigates Lipitor in Combination with Aricept in AD patients
6.6 Other Lipitor Significant Clinical Studies
6.7 Cardiovascular Disease
6.8 Paediatric Studies Demonstrated Significant Therapeutic benefits of Lipitor
6.9 Lipitor Post Marketing Studies

7 Lipitor Competitor Studies & Pipeline
7.1 Lipitor worldwide clinical studies
7.2 Competitor Agents in Development

8 Lipitor SWOT Analysis
8.1 Lipitor First Drug of Choice For Cholesterol Treatment
8.2 Lipid Regulator Market Will Continue to Generate High Revenues
8.3 An Expanding Patient Population Constitutes the Principal Driver in the Statins Market
8.4 Changes to Treatment Guidelines in US and Europe Can Benefit Sales Of Lipitor
8.5 The US Market Will Continue To Be Key for Lipitor’s Sales Growth
8.6 Generic Rivals Will Drive The Erosion of Lipitor’s Market Share
8.7 Pfizer And Astellas Reach Lipitor Settlement In Japan
8.8 US and EU Two -Year Statin Approval Timelines Increase Competitiveness
8.9 Lipitor A Testimony of The Crumbling Blockbuster Business Model
8.10 Pfizer Will Need Strategies That Will Yield High ROI After Lipitor’s Patent Expiration
8.11 New Reformulation Will be Significant To Drive Lipitor ’s Long-Term Revenues
8.12 Liptor Still Has Significant Developmental Possibilities
8.13 Lipitor’s Prominent Indications For Diverse Cardiovascular and Metabolic Areas Will be Significant For Future Sales
8.14 Lipitor Significant Trial Results Will Drive Sales
8.15 Is Pfizer’s Lipitor Success Repeatable?
8.16 US House of Democrats Investigate Lipitor’s Director-To-Customer Advertisement Campaign
8.17 OTC Simvastatin Adds To Lipitor’s Competition
8.18 Anti-Counterfeiting Initiatives Will Safeguard Lipitor in Emerging Markets
8.19 Lipitor Will Face Pricing Competition From Generic Statins

9 Conclusion
9.1 Lipitor (Atorvastatin) - The Cholesterol Reducing Drug
9.2 Lipid-regulating Drugs Generate The Highest Revenues In Cardiovascular Market
9.3 Statin Drugs Are Significant Market for Leading Pharmaceutical Companies
9.4 Lipitor (Atorvastatin) Is The World’s Highest Selling Drug
9.5 Lipitor Sales Are Most Significant In the US Market
9.6 Lipitor’s Faces Competition From Key Rivals
9.7 Non-Statin Drug Therapies Market Expands
9.8 Pfizer Using Product Lifecycle Management to Drive Sales of Lipitor
9.9 Caduet Positioned To Experience Strong Sales After Lipitor Expiration
9.10 Ranbaxy’s Successsful Patent Lawsuits Against Pfizer In Key Markets Will Be Costly To Lipitor’s Future Sales
9.11 Visiongain Concludes that Loyalty from Pfizer and Brand "Lipitor’s" Key Stakeholders Will Confer Future Sales